{"id":111611,"date":"2026-07-06T18:06:28","date_gmt":"2026-07-06T12:36:28","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=111611"},"modified":"2026-07-06T18:06:28","modified_gmt":"2026-07-06T12:36:28","slug":"centre-amends-drugs-rules-1945","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/centre-amends-drugs-rules-1945\/","title":{"rendered":"Centre Amends Drugs Rules 1945, Key Amendments, Significance"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">With rapid advances in biotechnology and precision medicine, new therapies such as stem cell treatments, gene therapy and animal tissue transplants are becoming increasingly important in modern healthcare. Recognising the need for stronger regulation of these advanced technologies, the <\/span><b>Central Government has amended the Drugs Rules, 1945 to bring Cell or Stem Cell-derived Products, Gene Therapeutic Products and Xenografts under the Centrally Licence Approving Authority (CLAA) framework. <\/b><span style=\"font-weight: 400;\">The amendment <\/span><b>aims to ensure uniform regulation, improve patient safety and promote responsible innovation in India\u2019s healthcare sector.<\/b><\/p>\n<h2><b>About the Drugs Rules, 1945<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The <\/span><span style=\"font-weight: 400;\">Drugs Rules, 1945<\/span><span style=\"font-weight: 400;\"> were framed under the <\/span><span style=\"font-weight: 400;\">Drugs and Cosmetics Act, 1940<\/span><span style=\"font-weight: 400;\"> to regulate the manufacture, import, sale, distribution and licensing of drugs and cosmetics in India.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Rules <\/span><b>provide the detailed procedures<\/b><span style=\"font-weight: 400;\"> for implementing the provisions of the Drugs and Cosmetics Act, 1940.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">They <\/span><b>prescribe standards for the manufacture, testing, storage, labelling, licensing and distribution <\/b><span style=\"font-weight: 400;\">of drugs, biological products and certain medical devices.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The Rules <\/span><b>aim to ensure that only safe, effective and quality medicines are made available<\/b><span style=\"font-weight: 400;\"> to the public.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">They <\/span><b>specify the roles and responsibilities<\/b><span style=\"font-weight: 400;\"> of the Central and State Licensing Authorities in granting and monitoring licences.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The Rules are amended periodically to accommodate new medical technologies, strengthen regulation and align with evolving national and international standards.<\/span><\/p>\n<h2><b>Key Amendments to Drugs Rules, 1945<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The amendment to the Drugs Rules, 1945 expands India\u2019s regulatory framework by bringing advanced medical products under stricter and uniform regulatory oversight.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Expanded the scope of CLAA<\/b><span style=\"font-weight: 400;\">: Cell or Stem Cell-derived Products, Gene Therapeutic Products and Xenografts have now been brought under the Centrally Licence Approving Authority (CLAA) framework.<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>Cell or Stem Cell-derived Products<\/b><span style=\"font-weight: 400;\">: Medicines developed from living cells or stem cells to repair or regenerate damaged tissues, such as stem cell therapy and CAR-T cell therapy.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>Gene Therapeutic Products<\/b><span style=\"font-weight: 400;\">: Medicines that treat diseases by repairing, replacing or modifying defective genes, especially for genetic disorders and certain cancers.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>Xenografts<\/b><span style=\"font-weight: 400;\">: Animal-derived tissues or organs, such as heart valves, that are transplanted into humans to replace damaged body parts.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">The <\/span><b>Centrally Licence Approving Authority (CLAA)<\/b><span style=\"font-weight: 400;\"> is a regulatory mechanism under the <\/span><b>Drugs and Cosmetics Act, 1940<\/b><span style=\"font-weight: 400;\"> through which the Central and State Licensing Authorities jointly regulate certain critical drugs and biological products.<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Joint regulation by Centre and States<\/b><span style=\"font-weight: 400;\">: These products will now be regulated jointly by the Central and State Licensing Authorities, ensuring better coordination in licensing, approval and monitoring across the country.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Uniform regulatory standards<\/b><span style=\"font-weight: 400;\">: The amendment establishes common quality, safety and efficacy standards so that patients receive the same level of protection and treatment quality in every State.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Enhanced regulatory scrutiny<\/b><span style=\"font-weight: 400;\">: Advanced therapies involving living cells, genes and animal tissues will now undergo more rigorous scientific evaluation, manufacturing inspections and safety assessments before approval.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Expansion of the existing CLAA framework<\/b><span style=\"font-weight: 400;\">: Earlier, the CLAA framework covered vaccines, large-volume parenterals (IV fluids above 100 ml) and <\/span><strong><a href=\"https:\/\/vajiramandravi.com\/upsc-exam\/recombinant-dna-technology\/\" target=\"_blank\">recombinant DNA (r-DNA)<\/a><\/strong><span style=\"font-weight: 400;\"> based medicines; the amendment expands this framework to include emerging medical technologies.<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><b>Recombinant DNA (r-DNA) medicines<\/b><span style=\"font-weight: 400;\">: Medicines produced using genetic engineering technology, such as insulin and certain monoclonal antibodies.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2><b>Why was this Amendment Needed?<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The rapid growth of regenerative medicine and gene-based therapies has created new opportunities for treating diseases that were previously considered difficult or impossible to cure. However, these therapies also involve greater scientific complexity and potential risks.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Advanced therapies involve living cells and genetic material, making their manufacturing and quality control much more complex than conventional medicines.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cell and gene therapies can produce long-term biological changes in the human body, making safety assessment more challenging.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Increasing use of <\/span><strong><a href=\"https:\/\/vajiramandravi.com\/upsc-exam\/car-t-cell-therapy\/\" target=\"_blank\">CAR-T cell therapy<\/a><\/strong><span style=\"font-weight: 400;\">, stem cell therapy and gene editing has created the need for specialised regulatory mechanisms.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Different licensing standards across States could lead to variations in quality and patient safety if a common regulatory framework is not adopted.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Global regulatory agencies are strengthening oversight of advanced therapies, making it essential for India to align with international best practices.<\/span><\/li>\n<\/ul>\n<h2><b>Significance of the Amendment<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The amendment strengthens India\u2019s regulatory framework for advanced medical technologies while ensuring that innovation is balanced with patient safety and public health.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Strengthens patient safety<\/b><span style=\"font-weight: 400;\">: Rigorous scientific evaluation and licensing will ensure that advanced therapies are safe, effective and of high quality before reaching patients.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Ensures uniform regulation across India<\/b><span style=\"font-weight: 400;\">: Bringing these products under the CLAA framework establishes common licensing, quality and safety standards across all States and Union Territories.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Strengthens regulatory oversight<\/b><span style=\"font-weight: 400;\">: Joint regulation by the Central and State Licensing Authorities improves monitoring, inspection and enforcement for complex biological products.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Facilitates faster adoption of advanced therapies<\/b><span style=\"font-weight: 400;\">: A clear regulatory pathway will enable safe introduction of innovative treatments such as stem cell therapies, gene therapies and xenografts into clinical practice.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Promotes innovation and research<\/b><span style=\"font-weight: 400;\">: A transparent and predictable regulatory environment encourages research institutions, biotechnology companies and pharmaceutical industries to develop advanced therapies.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Supports treatment of complex diseases<\/b><span style=\"font-weight: 400;\">: Improved regulation will facilitate wider availability of cutting-edge therapies for blood cancers, genetic disorders, cardiovascular diseases and orthopaedic conditions.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Build Public Confidence<\/b><span style=\"font-weight: 400;\">: Strong regulatory standards increase trust among patients and healthcare professionals in the safety and reliability of emerging therapies.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Aligns India with global best practices<\/b><span style=\"font-weight: 400;\">: The amendment modernises India\u2019s regulatory framework in line with internationally accepted standards for regulating advanced biological and regenerative medicines.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Boosts the biotechnology and life sciences sector<\/b><span style=\"font-weight: 400;\">: A robust regulatory system enhances India\u2019s competitiveness, attracts investment and supports growth in biotechnology, regenerative medicine and pharmaceutical innovation.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Contributes to public health security<\/b><span style=\"font-weight: 400;\">: Strong regulation ensures that emerging medical technologies are introduced responsibly while safeguarding public health and improving access to advanced healthcare.<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Centre amends Drugs Rules, 1945 to regulate stem cell therapies, gene therapies, and xenografts under CLAA, strengthening patient safety and healthcare standards.<\/p>\n","protected":false},"author":11,"featured_media":111645,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[786],"tags":[8543],"class_list":{"0":"post-111611","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-general-studies","8":"tag-centre-amends-drugs-rules-1945","9":"no-featured-image-padding"},"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/111611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=111611"}],"version-history":[{"count":3,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/111611\/revisions"}],"predecessor-version":[{"id":111628,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/111611\/revisions\/111628"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/111645"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=111611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=111611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=111611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}